Category Press Releases

WuXi Biologics Ireland Advances Sustainability Through Strategic Innovation

WuXi Biologics Ireland: Pioneering Sustainable Biomanufacturing Through Purpose-Driven Innovation In an era where sustainability has become a defining metric of corporate integrity and resilience, WuXi Biologics Ireland stands out as a biopharmaceutical leader integrating environmental, social, and governance (ESG) values…

Read MoreWuXi Biologics Ireland Advances Sustainability Through Strategic Innovation
TVC

TVC Partners with Norbrook to Bring Felanorm™ to Independent Veterinary Practices

TVC Partners with Norbrook to Bring Felanorm™ to Independent Veterinary Practices The Veterinary Cooperative (TVC), the premier group purchasing organization dedicated to supporting independent veterinary practices across the United States, is proud to announce a groundbreaking partnership with Norbrook Animal…

Read MoreTVC Partners with Norbrook to Bring Felanorm™ to Independent Veterinary Practices

Hansoh Pharma’s Ameile Approved for Fourth Use in EGFR+ NSCLC Adjuvant Therapy

Hansoh Pharma’s Ameile Gains Approval for New Indication in Early-Stage EGFR-Mutant NSCLC Hansoh Pharmaceutical Group Co., Ltd (03692.HK), hereafter referred to as Hansoh Pharma, announced that its innovative product Ameile (almonertinib mesylate tablets) has received approval in China for a…

Read MoreHansoh Pharma’s Ameile Approved for Fourth Use in EGFR+ NSCLC Adjuvant Therapy

Icotrokinra Shows Strong Results in Hard-to-Treat Scalp and Genital Psoriasis

Johnson & Johnson (NYSE: JNJ) today announced promising new results from the Phase 3 ICONIC-TOTAL study evaluating icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide designed to selectively block the IL-23 receptor. The study included adults and adolescents (12 years…

Read MoreIcotrokinra Shows Strong Results in Hard-to-Treat Scalp and Genital Psoriasis

Viatris Reports Positive Phase 3 Results for XULANE LO™ Low-Dose Birth Control Patch

A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal patch delivering 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol…

Read MoreViatris Reports Positive Phase 3 Results for XULANE LO™ Low-Dose Birth Control Patch

Imfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial

AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) for patients with high-risk non-muscle-invasive…

Read MoreImfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial